|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: UBQLN1 |
Gene summary for UBQLN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | UBQLN1 | Gene ID | 29979 |
| Gene name | ubiquilin 1 | |
| Gene Alias | DA41 | |
| Cytomap | 9q21.32 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | Q9UMX0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29979 | UBQLN1 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.91e-02 | 8.20e-01 | 0.3487 |
| 29979 | UBQLN1 | A015-C-203 | Human | Colorectum | FAP | 3.83e-14 | -3.04e-01 | -0.1294 |
| 29979 | UBQLN1 | A002-C-201 | Human | Colorectum | FAP | 4.83e-02 | -1.96e-01 | 0.0324 |
| 29979 | UBQLN1 | A001-C-108 | Human | Colorectum | FAP | 1.69e-09 | -2.63e-01 | -0.0272 |
| 29979 | UBQLN1 | A002-C-205 | Human | Colorectum | FAP | 3.94e-07 | -3.54e-01 | -0.1236 |
| 29979 | UBQLN1 | A015-C-006 | Human | Colorectum | FAP | 6.70e-04 | -3.22e-01 | -0.0994 |
| 29979 | UBQLN1 | A015-C-106 | Human | Colorectum | FAP | 6.82e-04 | -2.28e-01 | -0.0511 |
| 29979 | UBQLN1 | A002-C-114 | Human | Colorectum | FAP | 2.86e-05 | -3.30e-01 | -0.1561 |
| 29979 | UBQLN1 | A015-C-104 | Human | Colorectum | FAP | 8.09e-14 | -2.63e-01 | -0.1899 |
| 29979 | UBQLN1 | A001-C-014 | Human | Colorectum | FAP | 1.56e-06 | -2.56e-01 | 0.0135 |
| 29979 | UBQLN1 | A002-C-016 | Human | Colorectum | FAP | 1.70e-10 | -2.45e-01 | 0.0521 |
| 29979 | UBQLN1 | A015-C-002 | Human | Colorectum | FAP | 1.16e-02 | -2.60e-01 | -0.0763 |
| 29979 | UBQLN1 | A001-C-203 | Human | Colorectum | FAP | 7.63e-06 | -2.50e-01 | -0.0481 |
| 29979 | UBQLN1 | A002-C-116 | Human | Colorectum | FAP | 7.00e-17 | -2.79e-01 | -0.0452 |
| 29979 | UBQLN1 | A014-C-008 | Human | Colorectum | FAP | 2.28e-03 | -3.11e-01 | -0.191 |
| 29979 | UBQLN1 | A018-E-020 | Human | Colorectum | FAP | 2.45e-05 | -2.77e-01 | -0.2034 |
| 29979 | UBQLN1 | F034 | Human | Colorectum | FAP | 1.72e-12 | -3.14e-01 | -0.0665 |
| 29979 | UBQLN1 | F072B | Human | Colorectum | FAP | 1.08e-04 | -1.50e-01 | 0.257 |
| 29979 | UBQLN1 | LZE2T | Human | Esophagus | ESCC | 6.71e-05 | 4.33e-01 | 0.082 |
| 29979 | UBQLN1 | LZE4T | Human | Esophagus | ESCC | 1.96e-20 | 5.49e-01 | 0.0811 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004217634 | Oral cavity | NEOLP | regulation of protein catabolic process | 92/2005 | 391/18723 | 1.77e-13 | 5.27e-11 | 92 |
| GO:003133133 | Oral cavity | NEOLP | positive regulation of cellular catabolic process | 97/2005 | 427/18723 | 3.77e-13 | 1.07e-10 | 97 |
| GO:200124232 | Oral cavity | NEOLP | regulation of intrinsic apoptotic signaling pathway | 51/2005 | 164/18723 | 8.52e-13 | 2.02e-10 | 51 |
| GO:001049831 | Oral cavity | NEOLP | proteasomal protein catabolic process | 103/2005 | 490/18723 | 1.08e-11 | 1.65e-09 | 103 |
| GO:190336234 | Oral cavity | NEOLP | regulation of cellular protein catabolic process | 64/2005 | 255/18723 | 4.83e-11 | 6.11e-09 | 64 |
| GO:004316131 | Oral cavity | NEOLP | proteasome-mediated ubiquitin-dependent protein catabolic process | 89/2005 | 412/18723 | 6.27e-11 | 7.44e-09 | 89 |
| GO:000697933 | Oral cavity | NEOLP | response to oxidative stress | 94/2005 | 446/18723 | 7.53e-11 | 8.58e-09 | 94 |
| GO:004573233 | Oral cavity | NEOLP | positive regulation of protein catabolic process | 58/2005 | 231/18723 | 3.80e-10 | 3.18e-08 | 58 |
| GO:006219733 | Oral cavity | NEOLP | cellular response to chemical stress | 75/2005 | 337/18723 | 4.87e-10 | 3.97e-08 | 75 |
| GO:200005834 | Oral cavity | NEOLP | regulation of ubiquitin-dependent protein catabolic process | 46/2005 | 164/18723 | 5.31e-10 | 4.20e-08 | 46 |
| GO:004586233 | Oral cavity | NEOLP | positive regulation of proteolysis | 80/2005 | 372/18723 | 7.28e-10 | 5.54e-08 | 80 |
| GO:190305034 | Oral cavity | NEOLP | regulation of proteolysis involved in cellular protein catabolic process | 54/2005 | 221/18723 | 4.32e-09 | 2.49e-07 | 54 |
| GO:003243433 | Oral cavity | NEOLP | regulation of proteasomal ubiquitin-dependent protein catabolic process | 38/2005 | 134/18723 | 1.19e-08 | 5.70e-07 | 38 |
| GO:002241131 | Oral cavity | NEOLP | cellular component disassembly | 87/2005 | 443/18723 | 1.39e-08 | 6.46e-07 | 87 |
| GO:190336433 | Oral cavity | NEOLP | positive regulation of cellular protein catabolic process | 41/2005 | 155/18723 | 2.87e-08 | 1.22e-06 | 41 |
| GO:006113632 | Oral cavity | NEOLP | regulation of proteasomal protein catabolic process | 46/2005 | 187/18723 | 4.76e-08 | 1.95e-06 | 46 |
| GO:003459933 | Oral cavity | NEOLP | cellular response to oxidative stress | 61/2005 | 288/18723 | 1.33e-07 | 4.67e-06 | 61 |
| GO:003497632 | Oral cavity | NEOLP | response to endoplasmic reticulum stress | 56/2005 | 256/18723 | 1.39e-07 | 4.84e-06 | 56 |
| GO:007048232 | Oral cavity | NEOLP | response to oxygen levels | 69/2005 | 347/18723 | 2.66e-07 | 8.54e-06 | 69 |
| GO:000166632 | Oral cavity | NEOLP | response to hypoxia | 63/2005 | 307/18723 | 2.75e-07 | 8.78e-06 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa050146 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
| hsa041416 | Colorectum | MSI-H | Protein processing in endoplasmic reticulum | 46/797 | 174/8465 | 4.53e-11 | 9.78e-10 | 8.19e-10 | 46 |
| hsa050147 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
| hsa041417 | Colorectum | MSI-H | Protein processing in endoplasmic reticulum | 46/797 | 174/8465 | 4.53e-11 | 9.78e-10 | 8.19e-10 | 46 |
| hsa050148 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
| hsa041418 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
| hsa050149 | Colorectum | FAP | Amyotrophic lateral sclerosis | 91/1404 | 364/8465 | 1.84e-05 | 2.36e-04 | 1.44e-04 | 91 |
| hsa041419 | Colorectum | FAP | Protein processing in endoplasmic reticulum | 50/1404 | 174/8465 | 3.64e-05 | 3.68e-04 | 2.24e-04 | 50 |
| hsa04141211 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa04141310 | Esophagus | ESCC | Protein processing in endoplasmic reticulum | 147/4205 | 174/8465 | 3.29e-22 | 1.10e-19 | 5.64e-20 | 147 |
| hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0414114 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
| hsa0501414 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
| hsa0414115 | Liver | Cirrhotic | Protein processing in endoplasmic reticulum | 114/2530 | 174/8465 | 1.16e-22 | 9.67e-21 | 5.96e-21 | 114 |
| hsa0501415 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
| hsa0414122 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0501422 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
| hsa0414132 | Liver | HCC | Protein processing in endoplasmic reticulum | 146/4020 | 174/8465 | 7.34e-24 | 2.46e-21 | 1.37e-21 | 146 |
| hsa0501432 | Liver | HCC | Amyotrophic lateral sclerosis | 252/4020 | 364/8465 | 8.85e-18 | 7.41e-16 | 4.12e-16 | 252 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| UBQLN1 | SNV | Missense_Mutation | c.1615N>G | p.Gln539Glu | p.Q539E | Q9UMX0 | protein_coding | deleterious(0.02) | probably_damaging(0.943) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| UBQLN1 | SNV | Missense_Mutation | novel | c.1727N>C | p.Ile576Thr | p.I576T | Q9UMX0 | protein_coding | deleterious(0.05) | probably_damaging(0.995) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| UBQLN1 | SNV | Missense_Mutation | c.1642N>G | p.Gln548Glu | p.Q548E | Q9UMX0 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
| UBQLN1 | SNV | Missense_Mutation | c.914N>T | p.Ser305Phe | p.S305F | Q9UMX0 | protein_coding | deleterious(0) | possibly_damaging(0.736) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| UBQLN1 | SNV | Missense_Mutation | c.567C>G | p.Ile189Met | p.I189M | Q9UMX0 | protein_coding | tolerated(0.16) | benign(0.062) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| UBQLN1 | SNV | Missense_Mutation | rs764735825 | c.162G>T | p.Glu54Asp | p.E54D | Q9UMX0 | protein_coding | tolerated(0.45) | probably_damaging(0.976) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| UBQLN1 | SNV | Missense_Mutation | c.407A>C | p.Asn136Thr | p.N136T | Q9UMX0 | protein_coding | tolerated(0.8) | benign(0.01) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| UBQLN1 | SNV | Missense_Mutation | c.1363T>C | p.Ser455Pro | p.S455P | Q9UMX0 | protein_coding | deleterious(0.02) | possibly_damaging(0.849) | TCGA-AU-6004-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| UBQLN1 | SNV | Missense_Mutation | novel | c.560N>C | p.Val187Ala | p.V187A | Q9UMX0 | protein_coding | tolerated(0.66) | benign(0.278) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| UBQLN1 | SNV | Missense_Mutation | c.558N>T | p.Met186Ile | p.M186I | Q9UMX0 | protein_coding | deleterious(0.01) | benign(0.114) | TCGA-AZ-4614-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |